ArticleJACC. Case reports2025
Lipoprotein X: A Cause for Misleading Levels of Low-Density Lipoprotein.
Article in JACC. Case reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
- Erratum issued
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCholesterol metabolism plays a central role in the genesis of cardiovascular disease. Thus, it is critical that we understand the array of disorders that lead to its elevation. DISCUSSION: Most commonly, high levels of low-density lipoprotein cholesterol (LDL-C) are a consequence of polygenic variants often in association with lifestyle contributions. There are other less-common causes for elevated LDL-C which must also be considered such as heterozygous and homozygous familial hypercholesterolemia (heterozygous familial hypercholesterolemia and homozygous familial hypercholesterolemia, respectively), as well as sitosterolemia. The management of these disorders varies depending on etiology. Lipoprotein X (LpX) is an ultra-rare etiology of elevated LDL-C that can be seen in patients with significant liver disease and cholestasis. LpX occurs when an abnormal lipoprotein accumulates in patients with liver dysfunction and both intrahepatic and extrahepatic cholestasis. Lipoprotein X disrupts the feedback loop to trigger cholesterol synthesis inhibition leading to LDL-C levels that can exceed 1,000 g/dL. CASE SUMMARY: In this case study, we discuss a patient with LpX and consider the less-common causes of LDL-C elevation and how to manage them.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.